Volume 120, Issue 5 pp. 903-906

High-dose cyclophosphamide does not eradicate paroxysmal nocturnal haemoglobinuria haematopoiesis in mice carrying a Piga gene mutation

Anne Schaefer

Anne Schaefer

Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

Search for more papers by this author
Marek Jasinski

Marek Jasinski

Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

Search for more papers by this author
Monica Bessler

Monica Bessler

Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

Search for more papers by this author
First published: 03 March 2003
Citations: 1
Monica Bessler, MD, PhD, Division of Hematology, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Ave., Box 8125, St Louis, MO 63110–1093, USA. E-mail: [email protected]

Abstract

Summary. Recently, high-dose cyclophosphamide (HD CY) has been used in the treatment of aplastic anaemia. Several reports have suggested that the treatment may either eradicate or suppress mutant clonal haematopoiesis such as paroxysmal nocturnal haemoglobinuria (PNH). We therefore treated mice that have a proportion of blood cells deficient in GPI-anchor molecules (PIGA) with HD CY, and monitored their peripheral blood counts during and after treatment. HD CY produced a transient myelosuppression; however, the contribution of PIGA haematopoiesis to the peripheral blood remained unchanged, suggesting that HD CY is unlikely to eliminate an existing PNH clone in patients treated for aplastic anaemia.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.